Cargando…
Choosing wisely - when to mend a broken heart with ECMO?
Refractory cardiac shock in the cardiac surgical intensive care unit confers significant morbidity and mortality. Extracorporeal membrane oxygenation (ECMO) has become a common intervention for refractory cardiogenic shock when other therapies have failed. However, it is difficult to predict who wil...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059487/ https://www.ncbi.nlm.nih.gov/pubmed/24602370 http://dx.doi.org/10.1186/cc13736 |
_version_ | 1782321250029273088 |
---|---|
author | Stephens, R Scott Fan, Eddy |
author_facet | Stephens, R Scott Fan, Eddy |
author_sort | Stephens, R Scott |
collection | PubMed |
description | Refractory cardiac shock in the cardiac surgical intensive care unit confers significant morbidity and mortality. Extracorporeal membrane oxygenation (ECMO) has become a common intervention for refractory cardiogenic shock when other therapies have failed. However, it is difficult to predict who will benefit from this costly, resource-intensive, but potentially life-saving technology. Here, we discuss the utility of a novel biomarker, serum butylcholinesterase, in determining survival in patients supported with ECMO following cardiac surgery. |
format | Online Article Text |
id | pubmed-4059487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40594872015-02-20 Choosing wisely - when to mend a broken heart with ECMO? Stephens, R Scott Fan, Eddy Crit Care Commentary Refractory cardiac shock in the cardiac surgical intensive care unit confers significant morbidity and mortality. Extracorporeal membrane oxygenation (ECMO) has become a common intervention for refractory cardiogenic shock when other therapies have failed. However, it is difficult to predict who will benefit from this costly, resource-intensive, but potentially life-saving technology. Here, we discuss the utility of a novel biomarker, serum butylcholinesterase, in determining survival in patients supported with ECMO following cardiac surgery. BioMed Central 2014 2014-02-20 /pmc/articles/PMC4059487/ /pubmed/24602370 http://dx.doi.org/10.1186/cc13736 Text en Copyright © 2014 Stephens and Fan; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Stephens, R Scott Fan, Eddy Choosing wisely - when to mend a broken heart with ECMO? |
title | Choosing wisely - when to mend a broken heart with ECMO? |
title_full | Choosing wisely - when to mend a broken heart with ECMO? |
title_fullStr | Choosing wisely - when to mend a broken heart with ECMO? |
title_full_unstemmed | Choosing wisely - when to mend a broken heart with ECMO? |
title_short | Choosing wisely - when to mend a broken heart with ECMO? |
title_sort | choosing wisely - when to mend a broken heart with ecmo? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059487/ https://www.ncbi.nlm.nih.gov/pubmed/24602370 http://dx.doi.org/10.1186/cc13736 |
work_keys_str_mv | AT stephensrscott choosingwiselywhentomendabrokenheartwithecmo AT faneddy choosingwiselywhentomendabrokenheartwithecmo |